Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry

References

• Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, et al. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 69:89–95. doi:10.1067/mcp.2001.113989
   PubMed Web of Science ®Google Scholar
• Chirinos JA, Zhao L, Reese-Petersen AL, Cohen JB, Genovese F, Richards AM, Doughty RN, Díez J, González A, Querejeta R, et al. 2022. Endotrophin, a collagen VI formation–derived peptide, in heart failure. NEJM Evid. 1(10):1–12. doi:10.1056/evidoa2200091
   Google Scholar
• Dugger SA, Platt A, Goldstein DB. 2017. Drug development in the era of precision medicine. Nat Rev Drug Discov. 17(3):183–196. doi:10.1038/nrd.2017.226
   PubMed Web of Science ®Google Scholar
• EMA (CHMP). 2017. Essential considerations for successful qualification of novel methodologies. Amsterdam: European Medicines Agency.
   Google Scholar
• FDA (CDER/CBER). 2018. Biomarker qualification: evidentiary framework - draft guidance. p. 1–16.
   Google Scholar
• Fenton A, Jesky MD, Ferro CJ, Sørensen J, Karsdal MA, Cockwell P, Genovese F. 2017. Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. PLoS One. 12(4):e0175200. doi:10.1371/journal.pone.0175200
   PubMed Web of Science ®Google Scholar
• Genovese F, Karsdal MA. 2016. Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers. Expert Rev Proteomics. 13(2):213–225. doi:10.1586/14789450.2016.1134327
   PubMed Web of Science ®Google Scholar
• Henriksen K, Christiansen C, Karsdal MA. 2015. Role of biochemical markers in the management of osteoporosis. Climacteric. 18 Suppl 2(sup2):10–18. doi:10.3109/13697137.2015.1101256
   PubMedGoogle Scholar
• Jensen C, Madsen DH, Hansen M, Schmidt H, Svane IM, Karsdal MA, Willumsen N. 2018. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. J Immunother Cancer. 6(1):152. doi:10.1186/s40425-018-0474-z
   PubMedGoogle Scholar
• Karsdal MA, Anne-Christine B-J, Kim H, Leeming DJ, Nielsen Holm Signe BC. 2019. Biochemistry of collagens, laminins and elastin. London (UK); San Diego (CA): Elsevier.
   Google Scholar
• Karsdal MA, Delvin E, Christiansen C. 2011. Protein fingerprints - relying on and understanding the information of serological protein measurements. Clin Biochem. 44(16):1278–1279. doi:10.1016/j.clinbiochem.2011.08.1135
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Detlefsen S, Daniels SJ, Nielsen MJ, Krag A, Schuppan D. 2020. Is the total amount as important as localization and type of collagen in liver fibrosis attributable to steatohepatitis? Hepatology. 71(1):346–351. doi:10.1002/hep.30969
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Kraus VB, Shevell D, Bay-Jensen AC, Schattenberg J, Rambabu Surabattula R, Schuppan D. 2021. Profiling and targeting connective tissue remodeling in autoimmunity - a novel paradigm for diagnosing and treating chronic diseases. Autoimmun Rev. 20:102706.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Genovese F, Rasmussen DGK, Bay-Jensen AC, Mortensen JH, Holm Nielsen S, Willumsen N, Jensen C, Manon-Jensen T, Jennings L, et al. 2021. Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes. Clin Biochem. 97:11–24. doi:10.1016/j.clinbiochem.2021.08.007
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Bay-Jensen AC. 2019. Biochemical markers in osteoarthritis with lessons learned from osteoporosis. Clin Exp Rheumatol. 37 Suppl 120(5):73–87.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Genovese F, Leeming DJ, Nielsen MJ, Riis BJ, Christiansen C, Byrjalsen I, Schuppan D. 2017. Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes. Diabetologia. 60(1):50–59. doi:10.1007/s00125-016-4094-1
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Nielsen SH, Vongsuvanh R, Uchila P, Nielsen MJ, Reese-Petersen AL, van der Poorten D, Eslam M, Schuppan D, Karsdal MA, et al. 2021. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. Hepat Oncol. 8(2):HEP32.
   PubMed Web of Science ®Google Scholar
• Menetski JP, Hoffmann SC, Cush SS, Kamphaus TN, Austin CP, Herrling PL, Wagner JA. 2019. The Foundation for the National Institutes of Health Biomarkers Consortium: past accomplishments and new strategic direction. Clin Pharm Ther. 105(4):829–843. doi:10.1002/cpt.1362
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q, Suetta C, Henriksen K, Christiansen C, Karsdal MA, et al. 2013. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 5:303–315.
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Dolman GE, Harris R ,Frederiksen P ,Chalmers J ,Grove JI ,Irving WL ,Karsdal MA ,Patel K ,Leeming DJ, et al. 2023. PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Rep. 5(6):100743. doi:10.1016/j.jhepr.2023.100743
   PubMedGoogle Scholar
• Nissen NI, Kehlet S, Boisen MK, Liljefors M, Jensen C, Johansen AZ, Johansen JS, Erler JT, Karsdal M, Mortensen JH, et al. 2021. Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. Sci Rep. 11(1):865. doi:10.1038/s41598-020-79608-0
   PubMed Web of Science ®Google Scholar
• Pinzani M. 2008. Welcome to fibrogenesis & tissue repair. Fibrogenesis Tissue Repair. 1(1):1. doi:10.1186/1755-1536-1-1
   PubMedGoogle Scholar
• Project Optimus | FDA. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus.
   Google Scholar
• Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, et al. 2023. NAFLD and NASH biomarker qualification in the LITMUS consortium – lessons learned. J Hepatol. 78(4):852–865. doi:10.1016/j.jhep.2022.11.028
   PubMed Web of Science ®Google Scholar
• Rasmussen DGK, Fenton A, Jesky M, Ferro C, Boor P, Tepel M, Karsdal MA, Genovese F, Cockwell P. 2017. Urinary endotrophin predicts disease progression in patients with chronic kidney disease. Sci Rep. 7(1):17328. doi:10.1038/s41598-017-17470-3
   PubMedGoogle Scholar
• Rasmussen DGK, Hansen MK, Blair J, Jatkoe TA, Neal B, Karsdal MA, Genovese F. 2022. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial. Cardiovasc Diabetol. 21(1):261. doi:10.1186/s12933-022-01666-7
   PubMed Web of Science ®Google Scholar
• Reese-Petersen AL, Genovese F, Zhao L, Banks G, Gordon DA, Karsdal MA. 2023. Endotrophin, a fibroblast matrikine, may be a driver of fibroblast activation in fibro-inflammatory diseases. Front Mol Biosci. 10:1228232. doi:10.3389/fmolb.2023.1228232
   PubMed Web of Science ®Google Scholar
• Rønnow SR, Langholm LL, Karsdal MA, Manon-Jensen T, Tal-Singer R, Miller BE, Vestbo J, Leeming DJ, Sand JMB. 2020. Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. Respir Res. 21(1):202. doi:10.1186/s12931-020-01461-6
   PubMed Web of Science ®Google Scholar
• Sand JMB, Martinez G, Midjord A-K, Karsdal MA, Leeming DJ, Lange P. 2016. Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in clinically stable chronic obstructive pulmonary disease. Clin Biochem. 49(15):1144–1151. doi:10.1016/j.clinbiochem.2016.09.003
   PubMed Web of Science ®Google Scholar
• Scherer PE, Gupta OT. 2021. Endotrophin: Nominated for best supporting actor in the fibro-inflammatory saga. EBioMedicine. 69:103447. doi:10.1016/j.ebiom.2021.103447
   PubMed Web of Science ®Google Scholar
• Sparding N, Genovese F, Rasmussen DGK, Karsdal MA, Neprasova M, Maixnerova D, Satrapova V, Frausova D, Hornum M, Bartonova L, et al. 2022. Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 37(6):1099–1108. doi:10.1093/ndt/gfab163
   PubMed Web of Science ®Google Scholar
• Sparding N, Rasmussen DGK, Genovese F, Karsdal MA, Hornum M, Feldt-Rasmussen B, Packington R, Selby NM. 2022. Circulating levels of endotrophin are prognostic for long-term mortality after acute kidney injury. Kidney360. 3(5):809–817. doi:10.34067/KID.0000422021
   PubMedGoogle Scholar
• Staunstrup LM, Bager CL, Frederiksen P, Helge JW, Brunak S, Christiansen C, Karsdal M. 2021. Endotrophin is associated with chronic multimorbidity and all-cause mortality in a cohort of elderly women. EBioMedicine. 68:103391. doi:10.1016/j.ebiom.2021.103391
   PubMed Web of Science ®Google Scholar
• Sun K, Park J, Gupta OT, Holland WL, Auerbach P, Zhang N, Goncalves Marangoni R, Nicoloro SM, Czech MP, Varga J, et al. 2014. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun. 5:3485. doi:10.1038/ncomms4485
   PubMed Web of Science ®Google Scholar
• Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N. 2021. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J Transl Med. 19(1):39. doi:10.1186/s12967-021-02701-z
   PubMed Web of Science ®Google Scholar
• Wang YMC, Strauss DG, Huang SM. 2019. Use of pharmacodynamic/response biomarkers for therapeutic biologics regulatory submissions. Biomark Med. 13(10):805–809. doi:10.2217/bmm-2019-0197
   PubMed Web of Science ®Google Scholar
• Willumsen N, Thomsen LB, Bager CL, Jensen C, Karsdal MA. 2018. Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities. Cancer Immunol Immunother. 67(1):1–12. doi:10.1007/s00262-017-2074-z
   PubMed Web of Science ®Google Scholar
• Wong CH, Siah KW, Lo AW. 2019. Estimation of clinical trial success rates and related parameters. Biostatistics. 20(2):273–286. doi:10.1093/biostatistics/kxx069
   PubMed Web of Science ®Google Scholar
• Wynn TA. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 117(3):524–529. doi:10.1172/JCI31487
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gu X, Zhang N, Kolonin MG, An Z, Sun K. 2016. Divergent functions of endotrophin on different cell populations in adipose tissue. Am J Physiol Endocrinol Metab. 311(6):E952–E963. doi:10.1152/ajpendo.00314.2016
   PubMed Web of Science ®Google Scholar
• Ziv E, Durack JC, Solomon SB. 2016. The Importance of Biopsy in the Era of Molecular Medicine. Cancer J. 22(6):418–422. doi:10.1097/PPO.0000000000000228
   PubMed Web of Science ®Google Scholar